

Huntingtin proline-rich region modulation of Huntingtons disease pathogenesis

<https://www.neurodegenerationresearch.eu/survey/huntingtin-proline-rich-region-modulation-of-huntingtons-disease-pathogenesis/>

Principal Investigators

ZEITLIN, SCOTT

Institution

UNIVERSITY OF VIRGINIA

Contact information of lead PI

Country

USA

Title of project or programme

Huntingtin proline-rich region modulation of Huntingtons disease pathogenesis

Source of funding information

NIH (NINDS)

Total sum awarded (Euro)

€ 1,585,435.78

Start date of award

22/09/2014

Total duration of award in years

3

The project/programme is most relevant to:

Huntington's disease

Keywords

Proline-Rich Domain, Huntington gene, Huntington Disease, polyglutamine, Stretching

Research Abstract

? DESCRIPTION (provided by applicant): In Huntington's disease (HD), flanking protein domains modulate the toxicity of mutant Huntingtin's (HTT's) expanded polyQ stretch. In

mammals, a proline-rich region (PRR) is located at the C-terminal end of the polyQ stretch, and it has co-evolved with the polyQ stretch, increasing in size as the normal HTT polyQ stretch has lengthened during evolution. In yeast model systems, deletion of the HTT PRR in the context of an expanded polyQ stretch interferes with aggresome formation and increases toxicity of an N-terminal fragment of mutant HTT. To determine the role of the HTT PRR in modulating mutant HTT pathogenesis in mouse models for HD, we have generated three knock-in alleles of the mouse HD gene (*Hdh*) that express normal or mutant huntingtin (*htt*) with deletions of the PRR – *Hdh*?P, *Hdh*140Q?P, and *Hdh*3xFlag140Q?P. We have found, in contrast to the results of the yeast studies, that deletion of the mutant *htt* PRR ameliorates several phenotypes exhibited by the CAG140 knock-in mouse model for HD, resulting in a significant delay in aggregate formation, alterations in aggregate conformation, normalization of striatal Darpp-32 expression, and the rescue of activity deficits. Using these new mouse models, we propose three complementary aims to determine the mechanisms by which deletion of the *htt* PRR affects HD mouse model pathogenesis. In Aim 1, we will test the hypothesis that deletion of the PRR modulates mutant *htt*'s toxicity by altering the association of *htt*-interacting proteins. We propose using anti-FLAG immunoaffinity purification to enrich for proteins associating with 3xFlag140Q?P- *tt* and 3xFlag140Q-*htt* in the striatum and cortex, and characterize their identity using mass spectrometry. In addition, we will characterize the protein composition of *htt* aggregates purified from the *Hdh*140Q/+ and *Hdh*140Q?P/+ brain to determine if differential sequestration of cellular proteins by 140Q-*htt* and 140Q?P-*htt* aggregates contributes to pathogenesis. In Aim 2, we will test the hypothesis that deletion of the mutant *htt* PRR alleviates mutant *htt*'s perturbation of gene expression by performing RNA-seq analysis of wild-type, *Hdh*140Q/+, and *Hdh*140Q?P/+ striatal gene expression to identify those genes whose expression is altered in the *Hdh*140Q/+ brain but restored by the mutant *htt* PRR deletion in the *Hdh*140Q?P/+ brain. In Aim 3, we will genetically test the role of the *htt* PRR on aggresome formation (in cis or in trans), and the potential difference between the murine and human PRR in HD pathogenesis by characterizing behavior and neuropathology in *Hdh*140Q?P/?P, *Hdh*140Q?P/+, *Hdh*140Q?P/7QhuPRR and *Hdh*140Q?P/20QhuPRR mice as they age. In addition, we will characterize microtubule-based transport and autophagy (two pathways involved in aggresome formation and protein degradation) in early postnatal (P5) primary cortical and striatal neuronal cultures generated from wild-type, *Hdh*?P/?P, *Hdh*140Q/140Q and *Hdh*140Q?P/140Q?P mice.

Lay Summary

PUBLIC HEALTH RELEVANCE: Huntington's disease is caused by the expansion of a polyglutamine stretch within the protein Huntingtin. Neighboring protein domains influence the toxicity of Huntingtin's polyglutamine stretch, and we propose to determine how removing one of these domains, the proline-rich region (PRR), can rescue HD mouse model phenotypes. What we learn from this project will help us to devise new therapies for HD that target the Huntingtin PRR.

Further information available at:

Types:

Investments > €500k

Member States:

United States of America

Diseases:

Huntington's disease

Years:

2016

Database Categories:

N/A

Database Tags:

N/A